Lupin stocks fell over 2 per cent on Thursday after the India’s 1/3-largest drugmaker recalled over fifty four,000 vials of anti-bacterial injection Ceftriaxone in US.
The injections, manufactured at Lupin’s Mandideep facility in Madhya Pradesh had been recalled because of violation of modern appropriate manufacturing norms.
Lupin is likewise recalling 741 kg of Ceftriaxone Sodium (Sterile) energetic pharmaceutical, the present day enforcement report on USFDA site stated.
As of nine.41 a.m., Lupin stocks traded 1.1 in line with cent lower at Rs 1,415.35 apiece compared to zero.27 per cent fall inside the broader Nifty.
